stoxline Quote Chart Rank Option Currency Glossary
  
Oncolytics Biotech Inc. (ONCY)
1.06  0.03 (2.91%)    03-28 16:00
Open: 1.04
High: 1.06
Volume: 294,184
  
Pre. Close: 1.03
Low: 1.01
Market Cap: 80(M)
Technical analysis
2024-03-28 4:53:23 PM
Short term     
Mid term     
Targets 6-month :  1.37 1-year :  1.6
Resists First :  1.17 Second :  1.37
Pivot price 1.03
Supports First :  1 Second :  0.88
MAs MA(5) :  1.02 MA(20) :  1.03
MA(100) :  1.23 MA(250) :  1.69
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  42.2 D(3) :  38.6
RSI RSI(14): 51.4
52-week High :  3.39 Low :  0.87
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ONCY ] has closed below upper band by 15.3%. Bollinger Bands are 69% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.06 - 1.07 1.07 - 1.07
Low: 1 - 1 1 - 1.01
Close: 1.05 - 1.06 1.06 - 1.07
Company Description

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Headline News

Sun, 24 Mar 2024
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Movies UK

Sun, 10 Mar 2024
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 07 Mar 2024
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights - PR Newswire

Wed, 06 Mar 2024
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning - Yahoo Finance

Tue, 05 Mar 2024
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN - PR Newswire

Mon, 04 Mar 2024
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent ... - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 75 (M)
Shares Float 67 (M)
Held by Insiders 1.1 (%)
Held by Institutions 6.9 (%)
Shares Short 1,040 (K)
Shares Short P.Month 666 (K)
Stock Financials
EPS -0.31
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.37
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -55.5 %
Return on Equity (ttm) -102.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.45
Qtrly Earnings Growth 0 %
Operating Cash Flow -28 (M)
Levered Free Cash Flow -18 (M)
Stock Valuations
PE Ratio -3.54
PEG Ratio 0
Price to Book value 2.86
Price to Sales 0
Price to Cash Flow -2.82
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android